01 October 2014 : Review article
Efficacy and Safety of Bone Marrow Cell Transplantation for Chronic Ischemic Heart Disease: A Meta-Analysis
Chun Xiao ABCEF , Shijie Zhou ABE , Yueqiang Liu ADE , Huozhen Hu ABEDOI: 10.12659/MSM.892047
Med Sci Monit 2014; 20:1768-1777
Supplement Table 1 Characteristics of included studies.
| Study | Country | Sample size (I/C) | Average age (I/C) | NYHA classification | Duration (Mo) | Gender (male%) (I/C) | Revascularization | Baseline LVEF (mean SD) | Clinical scenario | Route of transplantation (no.) | No. of cells | Cell type | Imaging modality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ang et al., 2008 | UK | 42/20 | IM: 64.7/61.3; IC: 62.1/61.3 | N.A. | 6 | 86/14 | CABG | 25.4 (8.1) IM28.5 (6.5) IC | R-CIHD | IM(21)/IC(21) | 85±56×10 IM115±73×10 IC | BMMNC | MRI |
| Assmus et al., 2006 | Germany | 35/23 | 60/61 | 1–3 | 3 | 93/7 | PCI | 41 (11) | R-CIHD | IC | 205±110×10 | BMMNC | LVG |
| Chen et al., 2006 | China | 22/23 | N.A. | N.A. | 12 | N.A. | PCI | 26 (6) | R-CIHD | IC | 5×10 | MSC | Echo (EF) |
| Heldman et al., 2013 | US | MSC: 22/11BMMNC: 22/10 | MSC: 57.1/60.0BMMNC: 61.1/61.3 | 1–3 | 12 | MSC: 94.7/90.9BMMNC: 89.5/100 | N.A. | 35.9 (8.2) BMMNC35.7 (9.0) MSC | N-CIHD | IM | ≥100×10 | BMMNC/MSC | MRI |
| Hendrikx et al., 2006 | Belgium | 10/10 | 63.2/66.8 | N.A. | 4 | 100/70 | CABG | 42.9 (10.3) | R-CIHD | IM | 60.25± 31.35×10 | BMMNC | MRI |
| Lu et al., 2013 | China | 25/25 | 57/58 | 2–3 | 12 | 96/88 | CABG | 23.4 (7.1) | R-CIHD | IC | 13.38±8.14×10 | BMMNC | MRI |
| Maureira et al., 2012 | France | 7/7 | 58/57 | I: 2.1 (mean)C: 1.9 (mean) | 6 | 100/86 | CABG | 41 (8) | R-CIHD | IM | ≥300×10 | BMMNC | MRI |
| Patel et al., 2005 | Argentina | 10/10 | 64.8/63.6 | I: 3.5 C: 3.4 | 6 | 80/80 | CABG | 29.4 (3.6) | R-CIHD | IM | 22×10 (median) | CD34+ BMC | Echo |
| Perin et al., 2011 | America | 20/10 | 60.5/56.3 | I: 2.3 C: 2.6 | 6 | 80/50 | N.A. | 37.5 (8.2) | N-CIHD | IM | 30×10 | BMMNC | LVG |
| Perin et al., 2012a | America | 61/31 | 63.95/62.32 | 1–3 | 6 | 92/98 | N.A. | 32.43 (9.23) | N-CIHD | IM | 100×10 | BMMNC | Echo |
| Perin et al., 2012b | America | 10/10 | 58.2/57.8 | I: 2.5 C: 2.6 | 6 | 90/80 | N.A. | 36.1(10.9) | N-CIHD | IM | 0.29×10 | ALDHbr BMC | Echo/LVG |
| Pokushalov et al., 2010 | Russia | 55/54 | 61/62 | I: 3.3 C: 3.5 | 12 | 48/46 | N.A. | 27.8 (3.4) | N-CIHD | IM | 41±16×10 | BMMNC | Echo |
| Stamm et al., 2007 | Germany | 22/21 | 62/63.5 | 2–3 | 6 | 75/80 | CABG | 37.4 (8.4) | R-CIHD | IM | 5.86×10 (median) | CD133+ BMC | Echo |
| Tse et al., 2007 | China & Australia | 19/9 | 65.2/68.9 | I: 2–4C: 2–3 | 6 | 79/88 | N.A. | 45.7 (8.3) | N-CIHD | IM | 1.67±0.34×10 low4.20±2.80×10 high | BMMNC | MRI |
| van Ramshorst et al., 2009 | Netherlands | 25/25 | 64/62 | N.A. | 3 | 92/80 | N.A. | 56 (12) | N-CIHD | IM | 98±6×10 | BMMNC | MRI |
| Yao et al., 2008 | China | 24/23 | 54.8/56.3 | 1–3 | 6 | 96/96 | PCI | 44.3 (5.5) | R-CIHD | IC | 180×10 | BMMNC | MRI |
| Zhao et al., 2008 | China | 18/18 | 60.3/59.1 | 3–4 | 6 | 83.3/83.3 | CABG | 35.80 (7.28) | R-CIHD | IM | 6.59±5.12×10 | BMMNC | Echo |
| Bartunek et al., 2013 | Belgium/Serbia | 21/15 | 55.7/59.5 | 2–3 | 6 | 95.2/91.7 | N.A. | 27.5 (2) | N-CIHD | IM | >600×10 | MSC | Echo |
| Nasseri et al., 2014 | Germany | 30/30 | 61.9/62.7 | 1–4 | 6 | 93.3/96.7 | CABG | 27 (6) | R-CIHD | IM | 11.7×10 | CD133+ BMC | MRI |
| Pätilä et al., 2014 | Finland | 20/19 | 65/64 | 2–3 | 12 | 95/94.7 | CABG | 37.2 (4) | R-CIHD | IM | 8.4×10 (median) | BMMNC | MRI |
| I – Intervention; C – control; NYHA – New York Heart Association; LVEF – left ventricular ejection fraction; N.A. – not available; R-CIHD – revascularizable chronic ischemic heart disease; IM – intramyocardial; IC – intracoronary; CABG – coronary artery bypass grafting; BMC – bone marrow cell; BMMNC – bone marrow mononuclear cell; ALDHbr – with a high level of aldehyde dehydrogenase activity; MRI – magnetic resonance imaging; Echo – echocardiography; LVG – left ventriculography. | |||||||||||||